文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

环状 RNA KRT75 通过靶向 miR-659/CCAR2 轴增强鼻咽癌的顺铂化疗耐药性。

CircKRT75 augments the cisplatin chemoresistance of nasopharyngeal carcinoma via targeting miR-659/CCAR2 axis.

机构信息

Department of Oncology, Affiliated Hospital of Xiangnan University, Chenzhou, 423000, Hunan, China.

Department of Radiation Oncology, Affiliated Hospital of Xiangnan University, No.25 Renmin West Road, Beihu District, Chenzhou, 423000, Hunan, China.

出版信息

J Mol Histol. 2024 Nov 29;56(1):9. doi: 10.1007/s10735-024-10287-1.


DOI:10.1007/s10735-024-10287-1
PMID:39612069
Abstract

Cisplatin resistance is a clinical challenge limiting the treatment of nasopharyngeal carcinoma (NPC). CircRNAs have been evidenced as key molecules involved in tumor advancement and drug resistance. The present study aimed to elucidate the potential biological value of circKRT75 in NPC cisplatin resistance. CircKRT75 levels in NPC clinical samples and parental/resistant cell lines were analyzed based on qRT-PCR. CCK-8 and flow cytometry were adopted to assess the impacts of circKRT75 on the growth viability and apoptotic ability of NPC resistant cells. Meanwhile, western blot was performed to detect changes in the expression of apoptosis-related proteins. Bioinformatics analysis predicted miRNAs and mRNAs downstream of circKRT75, and the interaction between circKRT75 and downstream targets was validated by RNA pull-down, dual-luciferase reporter and rescue experiments. CircKRT75 was notably enhanced in NPC tissues and NPC cisplatin-resistant cells. Functional experiments disclosed that circKRT75 silencing repressed NPC-resistant cell growth and promoted apoptosis. Bioinformatics screening identified that circKRT75 performed as a molecular sponge for miR-659, and CCAR2 was a direct target of miR-659. Further rescue assays confirmed that miR-659 inhibitor restored the inhibitory effect of circKRT75 knockdown on the growth of drug-resistant cells, while CCAR2 silencing could reverse the promotion of NPC cisplatin resistance by circKRT75 upregulation. Additionally, animal experiments revealed that circKRT75 knockdown restrained NPC cisplatin resistance in vivo. CircKRT75 contributed to cisplatin resistance in NPC through miR-659/CCAR2 signaling, which provided a novel perspective and direction to solve the problem of chemoresistance in NPC.

摘要

顺铂耐药是限制鼻咽癌(NPC)治疗的临床挑战。CircRNAs 已被证明是参与肿瘤进展和耐药的关键分子。本研究旨在阐明 circKRT75 在 NPC 顺铂耐药中的潜在生物学价值。根据 qRT-PCR 分析 NPC 临床样本和亲本/耐药细胞系中的 circKRT75 水平。采用 CCK-8 和流式细胞术评估 circKRT75 对 NPC 耐药细胞生长活力和凋亡能力的影响。同时,进行 Western blot 检测凋亡相关蛋白表达的变化。生物信息学分析预测了 circKRT75 的下游 miRNA 和 mRNAs,通过 RNA 下拉、双荧光素酶报告基因和挽救实验验证了 circKRT75 与下游靶标的相互作用。CircKRT75 在 NPC 组织和 NPC 顺铂耐药细胞中明显增强。功能实验表明,circKRT75 沉默抑制 NPC 耐药细胞的生长并促进凋亡。生物信息学筛选鉴定出 circKRT75 作为 miR-659 的分子海绵,而 CCAR2 是 miR-659 的直接靶标。进一步的挽救实验证实,miR-659 抑制剂恢复了 circKRT75 敲低对耐药细胞生长的抑制作用,而 CCAR2 沉默可以逆转 circKRT75 上调对 NPC 顺铂耐药的促进作用。此外,动物实验表明,circKRT75 敲低抑制 NPC 顺铂耐药在体内。CircKRT75 通过 miR-659/CCAR2 信号通路促进 NPC 顺铂耐药,为解决 NPC 化疗耐药问题提供了新的视角和方向。

相似文献

[1]
CircKRT75 augments the cisplatin chemoresistance of nasopharyngeal carcinoma via targeting miR-659/CCAR2 axis.

J Mol Histol. 2024-11-29

[2]
MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.

BMC Cancer. 2020-6-26

[3]
Long Noncoding RNA HOXA11-AS Modulates the Resistance of Nasopharyngeal Carcinoma Cells to Cisplatin via miR-454-3p/c-Met.

Mol Cells. 2020-10-31

[4]
MiRNA-296-5p promotes the sensitivity of nasopharyngeal carcinoma cells to cisplatin via targeted inhibition of STAT3/KLF4 signaling axis.

Sci Rep. 2024-3-20

[5]
CircNRIP1 Modulates the miR-515-5p/IL-25 Axis to Control 5-Fu and Cisplatin Resistance in Nasopharyngeal Carcinoma.

Drug Des Devel Ther. 2021

[6]
Circular RNA circ_0008450 regulates the proliferation, migration, invasion, apoptosis and chemosensitivity of CDDP-resistant nasopharyngeal carcinoma cells by the miR-338-3p/SMAD5 axis.

Anticancer Drugs. 2022-1-1

[7]
RNF138 contributes to cisplatin resistance in nasopharyngeal carcinoma cells.

Sci Rep. 2025-1-9

[8]
miR-1278 sensitizes nasopharyngeal carcinoma cells to cisplatin and suppresses autophagy via targeting ATG2B.

Mol Cell Probes. 2020-10

[9]
LncRNA SNHG14 Facilitates Cisplatin Resistance Through Upregulating Notch2 via Binding to U2AF2 in Nasopharyngeal Carcinoma.

Head Neck. 2025-4

[10]
MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting SOX2.

Biol Chem. 2023-2-9

引用本文的文献

[1]
Tissue Factor Pathway Inhibitor 2 Enhances Hepatocellular Carcinoma Chemosensitivity by Activating CCAR2-GADD45A-Mediated DNA Damage Repair.

Int J Biol Sci. 2025-7-11

[2]
Circular RNAs as Targets for Developing Anticancer Therapeutics.

Cells. 2025-7-18

本文引用的文献

[1]
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.

Mol Cancer. 2024-1-22

[2]
CircGLIS3 inhibits thyroid cancer invasion and metastasis through miR-146b-3p/AIF1L axis.

Cell Oncol (Dordr). 2023-12

[3]
Mechanistic insights into the dual role of CCAR2/DBC1 in cancer.

Exp Mol Med. 2023-8

[4]
Circ_0001589/miR-1248/HMGB1 axis enhances EMT-mediated metastasis and cisplatin resistance in cervical cancer.

Mol Carcinog. 2023-11

[5]
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.

Lancet Oncol. 2023-7

[6]
Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal "unity of ecology and evolution" pathological ecosystem.

Theranostics. 2023

[7]
Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer.

Epigenetics. 2023-12

[8]
Circ_0000285 regulates nasopharyngeal carcinoma progression through miR-1278/FNDC3B axis.

Hum Exp Toxicol. 2023

[9]
circRNA_0067717 promotes paclitaxel resistance in nasopharyngeal carcinoma by acting as a scaffold for TRIM41 and p53.

Cell Oncol (Dordr). 2023-6

[10]
CircPDIA4 Induces Gastric Cancer Progression by Promoting ERK1/2 Activation and Enhancing Biogenesis of Oncogenic circRNAs.

Cancer Res. 2023-2-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索